Geistlich Pharma North America, Inc. Acquires Lynch Biologics, Llc, A Biologics And Tissue Engineering Company
Acquiring Company
Geistlich North America
Acquired Company
Lynch Biologics
Description
Geistlich Pharma North America announced today the acquisition of Lynch Biologics, LLC, the developer and sole provider of GEM 21S®, the first recombinant growth factor product for use in oral regenerative surgery. This acquisition further strengthens the regenerative product portfolio of Geistlich and provides significant growth potential.
Quick answer
Geistlich North America is acquiring Lynch Biologics, announced October 27, 2022.
- How much did Geistlich North America pay for Lynch Biologics?
- The deal value was not disclosed.
- What does Geistlich North America do?
- Geistlich Pharma North America brings the leader in regenerative dentistry directly to the United States and Canada.
Source: Fundz verified event record.
Other recent acquisitions in Manufacturing and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Collagen Matrix Acquires Polyganics (October 5, 2022)
- Boston Scientific Announces Strategic Investment To Acquire Majority Stake Of Acotec Scientific Holdings Limited (December 11, 2022)
- Abiogen Pharma Acquired Altamedics (December 8, 2022)
- Lilly Completes Acquisition Of Akouos Expanding Efforts To Help People With Genetic Diseases (December 1, 2022)
- Merck To Acquire Imago Biosciences, Inc. (November 21, 2022)
- Solesis Acquires Polyzen, Expanding Film And Coating Capabilities (November 2, 2022)
Who to call at Geistlich North America, and when
When Geistlich North America changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Geistlich North America raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Geistlich North America, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Geistlich North America. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Geistlich North America makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Lynch Biologics?
Lynch Biologics was acquired by Geistlich North America. The deal was reported on October 27, 2022. Geistlich Pharma North America brings the leader in regenerative dentistry directly to the United States and Canada. Geistlich North America is privately held and operates in Manufacturing.
When did Geistlich North America acquire Lynch Biologics?
Geistlich North America's acquisition of Lynch Biologics was reported on October 27, 2022. Geistlich Pharma North America announced today the acquisition of Lynch Biologics, LLC, the developer and sole provider of GEM 21S®, the first recombinant growth factor product for use in oral regenerative surgery. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Lynch Biologics do?
It is privately held, operating in Manufacturing.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.